References
- Costa OS, Salam T, Duhig A, et al. Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020;8(1):1738637.
- Dolinar R, Kohn CG, Lavernia F, et al. The non-medical switching of prescription medications. Postgrad Med. 2019;131(5):335–341.
- American Medical Association. Drug formularies and therapeutic interchange H-125.991. 2020. https://policysearch.ama-assn.org/policyfinder/detail/Drug%20Formularies%20and%20Therapeutic%20Interchange%20H-125.991?uri=%2FAMADoc%2FHOD.xml-0-227.xml
- American Medical Association. Prior authorization and utilization management reform principles. 2017.
- Nguyen E, Weeda ER, Sobieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32(7):1281–1290.
- Florentinus SR, Heerdink ER, van Dijk L, et al. Is new drug prescribing in primary care specialist induced? BMC Health Serv Res. 2009;9(1):6.
- Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982–990.
- Care AJoM. Express scripts dangles $500 to persuade patients to switch psoriasis drugs. Am J Manag Care. 2021; (Blog). https://www.ajmc.com/view/express-scripts-dangles-500-to-persuade-patients-to-switch-psoriasis-drugs
- Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med. 2015;372(25):2380–2382.
- Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ. 2014;15(S1):5–11.
- Pearson SD, Towse A, Lowe M, et al. Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals. J Comp Eff Res. 2021;10(7):537–547.
- Murphy A. Our Turn: health insurance bait and switch must end. Concord Monitor. [updated 2020 Feb 24; cited 2021 June 1]. https://www.concordmonitor.com/End-to-health-insurance-bait-and-switch-32842674
- Kwon T. Insurancy company switch your medication? Fight Back. [updated 2019 Jul 17; cited 2021 Jun 1]. https://diatribe.org/insurance-company-switch-your-medication-fight-back
- Skyrizi. Writing a tiered excepioin request letter. [updated Apr 2019; cited 2021 Aug 29]. https://www.skyrizihcp.com/content/dam/risahcp/pdfs/final/tiered-exception-letter-instructions-digital.pdf
- Weintraub A. Cigna’s $500 gift to psoriasis patients who switch to Eli Lilly’s Taltz is ‘rehearsal’ for Humira biosimilars: analyst. [updated 2021 Apr 6; cited 2021 May 15]. https://www.fiercepharma.com/pharma/cigna-s-500-gift-to-psoriasis-patients-who-switch-to-lilly-s-taltz-rehearsal-for-humira
- Udkoff J, Eichenfield LF. Cost-Effectiveness analysis of ixekizumab vs etanercept and their manufacturer-recommended dosing regimens in moderate to severe plaque psoriasis. J Drugs Dermatol. 2017;16(10):964–970.
- Swartenbroekx N, Farfan P, Espín J, et al. Incentives for market penetration of biosimilars in Belgium and in five European countries. J Pharm Belg. 2014;(4):36–46.
- Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
- Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20(1):155.
- Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756.
- Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676–683.
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. [cited 2021 Aug 1]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- European Medicines Agency. Guideline on similar biological medicinal products. [updated 2015 Nov 10; cited 2021 Aug 1]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- Food and Drug Administration. ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process. [cited 2021 Aug 1]. http://www.fda.gov/OHRMS/DOCKETS/98fr/2004d-0118-gdl0001.pdf
- Blauvelt A, Cohen AD, Puig L, et al. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. Br J Dermatol. 2016;174(2):282–286.
- Kheloussi S, Johns A, Parente V, et al. Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. JMCP. 2021;27(7):846–854.
- Rx KM. What is non-medical switching? Web. 2021 [updated 2021; cited 2021 Jun 6]. https://www.keepmyrx.org/issues/non-medical-switching/
- Mazzoni D, Vener C, Mazzocco K, et al. The psychological risks associated with the non-medical switch from biologics to biosimilars. Front Psychol. 2021;12:605643–605643.
- Petrie KJ, Rief W. Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol. 2019;70:599–625.
- Salam T, Duhig A, Patel AA, et al. Physicians’ perspectives regarding non-medical switching of prescription medications: results of an internet e-survey. Plos One. 2020;15(1):e0225867.
- Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016;10:937–948.
- Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.